Wellgistics Health, Inc. reported its financial results for the third quarter of 2025 and provided insights into its business strategies and developments.
The company's focus on launching Brenzavvy® for the Type 2 diabetes market and leveraging EinsteinRx™ AI pharmacy hub software to reduce out-of-pocket costs for patients.
Wellgistics Health is advancing its technology integration and preparing for a significant milestone in 2026 with the PharmcyChain™ smart contracts platform.
Launch of Brenzavvy®
Targeting the Type 2 diabetes market to address out-of-pocket cost constraints and drive revenue growth.
Technology Advancements
Successful finalization of EinsteinRx™ by the tech team led by Srini Kalla to enhance client services.
Blockchain Smart Contracts Strategy
Advanced discussions with DataVault AI for a license agreement to support healthcare efficiency through blockchain technology.
- Expanding into the $2 trillion US Wellness Market to diversify healthcare services.
- Partnerships with Tollo Health and strategic acquisitions to enhance GLP-1 offerings and address major side effects.
- Expected launch of muscle loss-mitigating GLP-1 side effect product and distribution of Tollovid™ for Long COVID patients.
Wellgistics Health's proactive strategies and product developments position it for growth and innovation in the healthcare market.